Welcome to our dedicated page for Pharvaris N.V. SEC filings (Ticker: PHVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pharvaris N.V. (PHVS) SEC filings page on Stock Titan brings together the company’s U.S. regulatory disclosures as a foreign private issuer listed on Nasdaq. Pharvaris files annual reports on Form 20-F and furnishes interim updates on Form 6-K under the Securities Exchange Act of 1934, providing investors with information on its late-stage biopharmaceutical operations and capital markets activity.
Through Forms 6-K, Pharvaris furnishes press releases on financial results and business updates, including quarterly IFRS-based financial statements, management’s discussion and analysis, and details on cash runway and research and development spending. These filings also cover outcomes of the company’s Annual General Meeting of Shareholders, auditor appointments, and board-related matters.
Filings related to capital raising and securities include descriptions of underwritten public offerings of ordinary shares and pre-funded warrants, underwriting agreements, pre-funded warrant terms, and associated legal opinions. For example, Pharvaris has used an effective shelf registration statement on Form F-3 and Form F-3ASR to register offerings that fund late-stage clinical programs, commercialization preparation, and general corporate purposes.
For its core therapeutic focus, investors can use Pharvaris filings alongside AI-powered summaries to understand disclosures around clinical development of deucrictibant for hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). While detailed clinical data are often first released via press releases, they are also referenced in 6-K reports that are incorporated by reference into the company’s registration statements.
Stock Titan’s tools can help interpret these documents by highlighting key points from lengthy exhibits, such as interim financial statements, registration rights agreements, and offering documentation. Real-time updates from EDGAR, combined with AI-generated explanations, allow users to quickly review new Pharvaris filings, track how the company finances its late-stage pipeline, and monitor changes in its registered securities.
Pharvaris N.V.’s Principal Accounting Officer Anna Nijdam reported a routine tax-related share disposition. On the vesting of restricted stock units, 1,164 shares of common stock were withheld by the company at $28.25 per share to cover tax withholding obligations. After this withholding, Nijdam directly holds 50,655 shares of Pharvaris common stock. This was not an open-market sale but an administrative step tied to equity compensation.
Pharvaris N.V. insider Stefan Andreas Abele, Chief Technical Ops Officer, filed an amended ownership report. The amendment corrects his holdings to reflect 49,216 shares of Common Stock beneficially owned directly after certain restricted stock units vested and related tax settlement timing delayed their appearance in the original filing.
Pharvaris N.V., a Netherlands-based late-stage biopharmaceutical company, files its annual report outlining risks and strategy as it advances deucrictibant in immediate-release capsules and extended-release tablets for hereditary angioedema (HAE). The company remains pre-revenue, has incurred significant losses and expects continued operating losses for several years.
Pharvaris emphasizes heavy dependence on deucrictibant, notes prior U.S. clinical holds that were lifted after additional toxicology work, and highlights potential delays or failures in late-stage trials. It reports 65,210,590 ordinary shares outstanding as of December 31, 2025, and warns that additional capital will be needed, potentially diluting shareholders or forcing pipeline cuts.
Pharvaris reported a larger 2025 loss while advancing its late-stage HAE pipeline. Cash and cash equivalents were €291.7 million as of December 31, 2025, up from €281 million a year earlier, supporting ongoing Phase 3 programs.
R&D expenses rose to €34.1 million in the fourth quarter and €124.5 million for 2025, reflecting investment in pivotal studies, while G&A expenses were €13.5 million in the quarter and €45.3 million for the year. The company reported a fourth-quarter loss of €46.7 million and a full-year loss of €175.7 million, with basic and diluted loss per share of €0.72 and €2.97, respectively.
Pharvaris completed enrollment in CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for prophylactic treatment of hereditary angioedema (HAE), with topline data anticipated in the third quarter of 2026, and plans to submit a U.S. NDA for deucrictibant IR for on-demand HAE treatment in the first half of 2026.
Pharvaris N.V. director Robert Glassman filed an initial ownership report showing his existing equity position. He reports several stock option awards on common stock, including options over 16,500 shares at an exercise price of $28.00, 15,000 shares at $16.05, 14,000 shares at $22.31, 21,000 shares at $8.05, 14,493 shares at $18.14, and 8,000 shares at $20.00, with expirations between 2031 and 2036. He also holds 23,300 option-underlying shares at $7.89 and 15,167 shares of common stock directly, plus 5,500 restricted stock units that will fully vest on March 3, 2027.
Pharvaris N.V. director Johannes Schikan reports his beneficial holdings in the company. He directly holds 395,167 shares of Common Stock, which includes restricted stock units that will settle in common shares.
He also holds several stock options to buy common shares, including 16,500 shares at an exercise price of $28.0000 per share expiring in 2036, 15,000 shares at $16.0500 expiring in 2035, 14,000 shares at $22.3100 expiring in 2034, 21,000 shares at $8.0500 expiring in 2033, 17,500 shares at $18.1400 expiring in 2032, and 35,000 shares at $20.0000 expiring in 2031. A grant of 5,500 restricted stock units from March 3, 2026 is scheduled to vest on March 3, 2027.
Pharvaris N.V. director Elisabeth Bjork filed an initial ownership report detailing her equity position in the company. She directly holds 15,167 shares of common stock, along with several stock option awards and restricted stock units granted under the company’s equity plan.
Her option holdings cover common shares at exercise prices of $8.05, $14.39, $18.14, $22.31, $16.05, and $28.00, with expiration dates ranging from 2032 to 2036. Footnotes explain that vesting schedules vary by grant, with one award vesting 100% on its 12‑month anniversary and others vesting 25% initially, then in monthly installments. The report also notes 5,500 restricted stock units from an award granted March 3, 2026, which are scheduled to vest in full on March 3, 2027 and settle in common shares.
Pharvaris N.V. filed an initial ownership report for its CFO / CLO, Nassif David W., detailing his current equity position in the company. He directly holds 123,925 shares of common stock and several stock option grants over Pharvaris shares.
These options cover 60,000 shares at $28.00 per share expiring in 2036, 60,000 shares at $16.05 expiring in 2035, 75,000 shares at $15.94 expiring in 2034, and 230,000 shares at $20.15 also expiring in 2034. The common share holdings include restricted stock units that vest over time, such as a 20,000-unit award granted in March 2026 with 25% vesting in March 2027 and the remainder vesting monthly.
Pharvaris N.V. executive Stefan Andreas Abele, Chief Technical Ops Officer, reports his initial equity holdings. He holds several stock option awards over common shares, including options exercisable at $28.0000, $16.0500, $22.3100 and $16.4000, with expiration dates between November 15, 2033 and March 3, 2036. These options cover 60,000, 60,000, 40,000 and 89,500 underlying common shares, respectively. He also reports direct ownership of 43,942 shares of common stock as of March 18, 2026, which includes restricted stock units granted under the company’s equity plan that vest over time according to the schedules described in the footnotes.
Pharvaris N.V. executive Dr. Anne Lesage, Chief Early Development, filed an initial Form 3 reporting her ownership in the company. She lists multiple stock option awards on common stock, including grants covering 60,000 shares at an exercise price of $28.0000 expiring on March 3, 2036 and other options with exercise prices ranging from $2.5900 to $22.3100. She also reports Common Stock holdings of 56,450 shares directly and 163,969 shares indirectly through GrayMatters Consulting B.V. Footnotes note outstanding restricted stock units from prior awards that settle in common shares with time-based vesting schedules.